Form 8-K

ARIAD Pharmaceuticals, Inc.

/s/ Manmeet S. Soni

Manmeet S. Soni

Executive Vice President,

Chief Financial Officer and Treasurer

0001193125-16-554141.txt : 20160425 0001193125-16-554141.hdr.sgml : 20160425 20160425160636 ACCESSION NUMBER: 0001193125-16-554141 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160425 ITEM INFORMATION: Other Events FILED AS OF DATE: 20160425 DATE AS OF CHANGE: 20160425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36172 FILM NUMBER: 161589101 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d179213d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 25, 2016

ARIAD Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-36172	22-3106987
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

26 Landsdowne Street, Cambridge, Massachusetts		02139
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 494-0400

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01

Other Events.

Frank G. Haluska, M.D., Ph.D., the Senior Vice President, Clinical Research and Development and Chief Medical Officer of ARIAD Pharmaceuticals, Inc. (the “Company”), has resigned from the Company, effective as of May 6, 2016, to take a position as chief executive officer of an oncology company. Sergio Santillana, M.D., the Company’s Vice President, Clinical R&D, has been appointed as Acting Chief Medical Officer, effective upon Dr. Haluska’s departure, and reporting to Timothy P. Clackson, Ph.D., President of Research and Development and Chief Scientific Officer.

Thomas J. DesRosier, Esq., the Company’s Executive Vice President, Chief Legal and Administrative Officer and Secretary, has resigned from the Company, effective as of April 30, 2016, to pursue other opportunities. Scott A. Samuels, Esq., the Company’s Assistant General Counsel, has been appointed as Acting General Counsel and Secretary, effective upon Mr. DesRosier’s departure.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 25, 2016